IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE) — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE) — Stella

Recruiting

Back to Refractory Systemic Lupus Erythematosus trials

Not a traditional drug trial — this study doesn't follow the standard phase structure.

Trial locations(1 site)

China

Peking Universitiy Third Hospital, Beijing, Beijing Municipality

Key details

Sponsor

Peking University Third Hospital

Enrollment target

~6 participants

Started

July 2024

Primary completion

December 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 65 Years

Last updated August 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov